Amendments to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

Listing of the Claims:

1-16. (Cancelled).

17. (Previously presented) A compound of formula (I),



(I)

the *N*-oxide forms, the addition salts and the stereo-chemically isomeric forms thereof, wherein

n is 0, 1 or 2;

X is N or CR^7, wherein R^7 is hydrogen or taken together with R^1 may form a bivalent radical of formula -CH=CH-CH=CH-;

R^1 is C_{1-6}alkyl or thiophenyl;

R^2 is hydrogen, hydroxy, C_{1-6}alkyl, C_{3-6}alkynyl or taken together with R^3 may form =O;

except that when X is N, R^2 together with R^3 cannot form =O;

R^3 is a radical selected from

$-(CH_2)_s-NR^8R^9$	(a-1),
-O-H	(a-2),
$-O-R^{10}$	(a-3),
$-S-R^{11}$	(a-4), or
—C≡N	(a-5),

wherein

s is 0, 1, 2 or 3;

R^8, R^{10} and R^{11} are each independently selected from –CHO, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{1-6}alkylcarbonyl, amino, C_{1-6}alkylamino,

di(C_{1-6}alkyl)aminoC_{1-6}alkyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylcarbonylaminoC_{1-6}alkyl, piperidinylC_{1-6}alkylaminocarbonyl, piperidinyl, piperidinylC_{1-6}alkyl, piperidinylC_{1-6}alkylaminocarbonyl, C_{1-6}alkyloxy, thiophenylC_{1-6}alkyl, pyrrolylC_{1-6}alkyl, arylC_{1-6}alkylpiperidinyl, arylcarbonylC_{1-6}alkyl, arylcarbonylpiperidinylC_{1-6}alkyl, haloindozolylpiperidinylC_{1-6}alkyl, arylC_{1-6}alkyl(C_{1-6}alkyl)aminoC_{1-6}alkyl, and

R^9 is hydrogen or C_{1-6}alkyl;

or R^3 is a group of formula

$$-(CH_2)_t\text{-}Z \qquad \text{(b-1)},$$

wherein

t is 0, 1, 2 or 3;

-Z is a heterocyclic ring system selected from


(c-1)

(c-3)


(c-5)


(c-6)


(c-7)


(c-8)


(c-9)


(c-10)


(c-11)

wherein R^{12} is hydrogen, halo, C_{1-6}alkyl, aminocarbonyl, amino, hydroxy, aryl,



C_{1-6}alkylaminoC_{1-6}alkyloxy, C_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkylamino, arylC_{1-6}alkyl, di(phenylC_{2-6}alkenyl), piperidinyl, piperidinylC_{1-6}alkyl, C_{3-10}cycloalkyl, C_{3-10}cycloalkylC_{1-6}alkyl, aryloxy(hydroxy)C_{1-6}alkyl, haloindazolyl, arylC_{1-6}alkyl, arylC_{2-6}alkenyl, arylC_{1-6}alkylamino, morpholino, C_{1-6}alkylimidazolyl, pyridinylC_{1-6}alkylamino; and

R^{13} is hydrogen, piperidinyl or aryl;

R^4, R^5 and R^6 are each independently selected from hydrogen, halo, trihalomethyl, trihalomethoxy, C_{1-6}alkyl, C_{1-6}alkyloxy, amino, aminoC_{1-6}alkyl, di(C_{1-6}alkyl)amino, di(C_{1-6}alkyl)aminoC_{1-6}alkyloxy or C_{1-6}alkyloxycarbonyl, or C_{1-6}alkyl substituted with 1, 2 or 3 substituents independently selected from hydroxy, C_{1-6}alkyloxy, or aminoC_{1-6}alkyloxy; or

when R^5 and R^6 are on adjacent positions they may taken together form a bivalent radical of formula

-O-CH_2-O (d-1),

-O-$(CH_2)_2$-O- (d-2),

-CH=CH-CH=CH- (d-3), or

-NH-C(O)-NR^{14}=CH- (d-4),

wherein R^{14} is C_{1-6}alkyl;

and aryl is phenyl, phenyl substituted with halo, C_{1-6}alkyl or C_{1-6}alkyloxy.

18. (Currently Amended) A compound as claimed in claim 17 wherein

R^1 is C_{1-6}alkyl; R^3 is a radical selected from <u>the group consisting of</u> (a-1), (a-2), (a-3) ~~or~~ (a-5), <u>and</u> ~~or is a group of formula~~ (b-1) <u>wherein -Z is a heterocyclic ring system selected from (c-1), (c-6), (c-8), (c-9), or (c-11);</u> s is 0, 1 or 2; R^8 and R^{10} are each independently selected from

–CHO, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, di(C_{1-6}alkyl)aminoC_{1-6}alkyl,

C_{1-6}alkylcarbonylaminoC_{1-6}alkyl, piperidinylC_{1-6}alkyl, piperidinylC_{1-6}alkylaminocarbonyl, C_{1-6}alkyloxy, thiophenylC_{1-6}alkyl, pyrrolylC_{1-6}alkyl, arylC_{1-6}alkylpiperidinyl, arylcarbonylC_{1-6}alkyl, arylcarbonylpiperidinylC_{1-6}alkyl, haloindozolylpiperidinylC_{1-6}alkyl, or arylC_{1-6}alkyl(C_{1-6}alkyl)aminoC_{1-6}alkyl; t is 0 or 2; ~~-Z is a heterocyclic ring system selected from (c-1), (c-2), (c-4), (c-6), (c-8), (c-9), or (c-11);~~ R^{12} is hydrogen,



C_{1-6}alkyl, aminocarbonyl, , C_{1-6}alkyloxyC_{1-6}alkylamino, di(phenylC_{2-6}alkenyl), piperidinylC_{1-6}alkyl, C_{3-10}cycloalkyl, C_{3-10}cycloalkylC_{1-6}alkyl, haloindazolyl, or arylC_{2-6}alkenyl; R^4, R^5 and R^6 are each independently selected from hydrogen, halo, trihalomethyl, trihalomethoxy, C_{1-6}alkyl, C_{1-6}alkyloxy, di(C_{1-6}alkyl)amino, di(C_{1-6}alkyl)aminoC_{1-6}alkyloxy or C_{1-6}alkyloxycarbonyl; and when R^5 and R^6 are on adjacent positions they may taken together form a bivalent radical of formula (d-1) or (d-2).

19. (Currently Amended) A compound according to claim 17 wherein n is 0; X is CH; R^1 is C_{1-6}alkyl; R^2 is hydrogen; ~~R^3 is a group of formula (b-1)~~ wherein -Z is a heterocyclic ring system selected from (c-1); t is 2; ~~-Z is a heterocyclic ring system selected from (c-1);~~ R^{12} is hydrogen; R^{13} is hydrogen; and R^5 and R^6 are on adjacent positions and taken together form a bivalent radical of formula (d-2).

20. (Previously Presented) A compound selected from compounds No 16, compound No 144, and compound No. 145:



compound 16



Compound 144



Compound 145

21. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 17.

22. (Currently Amended) A combination of a compound as claimed in Claim 17 with a chemotherapeutic agent selected from the group consisting of 5-fluroourcil, leucovorin, 5'-amnio-5'deoxythymidine, carbogen, oxygen, Flucosol 10 DA, 2,3-DPG, BW12C, cisplatin, bleomycin, pentoxyfyline, hydrolazine, LBSO, calcium channel blockers, methylating agents, and toposisomerse 1 inhibitors.